crc

MRTX-1719 is a potent and selective inhibitor of the PRMT5/MTA complex with an IC50 value of <10 nM against PRMT5/MTAMTAPDELSDMA cell lines.

TNO155 is a protein tyrosine phosphatase (PTP) non-receptor type 11 (SHP2; src homology region 2 domain phosphatase; PTPN11) inhibitor(IC50 : 0.011 µM),with potential antineoplastic activity.

Sulindac (Sulindac sulfoxide) is a sulfinylindene derivative prodrug with potential antineoplastic activity. Converted in vivo to an active metabolite, sulindac, a nonsteroidal anti-inflammatory drug (NSAID), blocks cyclic guanosine monophosphate-phosphodiesterase (cGMP-PDE), an enzyme that inhibits the normal apoptosis signal pathway; this inhibition permits the apoptotic signal pathway to proceed unopposed, resulting in apoptotic cell death.

Combretastatin A4 (CA4) is a microtubule-targeting agent that binds β-tubulin (Kd: 0.4 μM).

Amphethinile, an anti-tubulin agent, has a Ka with tubulin of 1.3 μM.

XR-5000 is a DNA topoisomerase I and II inhibitor.

Liensinine is the active constituent of plumula nelambinis with anti-hypertension.

CRC-IN-1 (compound (-) -15h) is an effective agent against colorectal cancer (CRC) both in vitro and in vivo, and it is a derivative of the anticancer substance Evodiamine.

1H-Benzimidazole-6-carboxamide, N-[3-(aminocarbonyl)-4,5,6,7-tetrahydrobenzo[b]thien-2-yl]- may have antitumor activity.

GGASCCLYCRCH is a bioactive peptide that can inhibit the 2-O-methyltransferase activity within the SARS-CoV nsp16/10 complex.

The Anti-MUC1/CD227 Antibody (C595 (NCRC48)) is a chimeric mouse IgG3, κ antibody targeting human MUC1/CD227. Its isotype control is the Mouse IgG3 kappa, Isotype Control.

Cetuximab (C225) is a monoclonal antibody that is an inhibitor of human epidermal growth factor receptor (EGFR) (Kd=0.201 nM). Cetuximab has antitumor activity, inhibiting tumor cell proliferation and inducing apoptosis.

RO-3306 is a selectivity ATP-competitive CDK1 inhibitor (Ki: 20 nM). The selectivity of RO-3306 for CDK1 is >15-fold higher than a diverse panel of human kinases.

Ac-rC Phosphoramidite can modify phosphodisulfide oligonucleotides.

FKBP12 PROTAC RC32 is a PROTAC-like degrader targeting FKBP12. It can degrade FKBP12 in organs after intraperitoneal administration.

Crenigacestat (LY3039478) is an orally bioavailable Notch inhibitor with an IC50 of ~1 nM in most tumor cell lines tested. It effectively inhibits mutant Notch receptor activity and, in a xenograft tumor model, inhibits the expression of Notch-regulated genes and N1ICD cleavage in the tumor microenvironment.

5'-O-DMT-2'-O-TBDMS-Ac-rC is a modified nucleoside that can be utilized in the synthesis of DNA or RNA. 5'-O-DMT-2'-O-TBDMS-Ac-rC is applicable to oligonucleotide chemistry, nucleic acid engineering, RNA modification studies, and synthetic biology-related research workflows.

5'-O-DMT-3'-O-TBDMS-Ac-rC is a modified nucleoside used for synthesizing DNA or RNA.

CPTH2 is a histone acetyltransferase inhibitor modulating Gcn5 network.

IMT1 (Propanamide, N,N-dimethyl-2-[[4-(2-methylphenyl)-2-oxo-2H-1-benzopyran-7-yl]oxy]-) has anticancer activity.

GSK484 hydrochloride (GTPL8577) is a reversible peptidyl-arginine deiminase 4 (PAD4) inhibitor. It binds to PAD4 with high affinity, with IC50 of 250 and 50 nM in the presence and absence of 2 mM calcium, respectively. GSK484 promotes the radiosensitivity of colorectal cancer (CRC) and inhibits NET formation in vitro and in vivo.

AQ4 is a topoisomerase II inhibitor and DNA-inserting agent that displays antitumor activity in CRC cell lines.

SFI003 is a small-molecule inhibitor and an SRSF3 inhibitor with favorable pharmacokinetic properties, bioavailability, and tumor distribution capacity, inducing apoptosis in colorectal cancer cells through the SRSF3/DHCR24/ROS axis and exhibiting potent antitumor activity.